Theratechnologies Stock Price, News & Analysis (NASDAQ:THTX)

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" THTX shares.
View THTX analyst ratings or view top-rated stocks.

Theratechnologies' stock was trading at $3.5312 at the start of the year. Since then, THTX shares have decreased by 51.9% and is now trading at $1.70.
View the best growth stocks for 2023 here.

Theratechnologies saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 34,000 shares, a decline of 82.6% from the October 31st total of 195,400 shares. Based on an average daily trading volume, of 332,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.2% of the company's shares are short sold.
View Theratechnologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our THTX earnings forecast.

Theratechnologies Inc. (NASDAQ:THTX) released its earnings results on Tuesday, September, 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.46. The firm earned $20.86 million during the quarter. During the same period last year, the business posted ($0.32) EPS.

Shares of Theratechnologies reverse split before market open on Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Theratechnologies issued an update on its FY 2023 earnings guidance on Tuesday, September, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $82.00 million-$85.00 million, compared to the consensus revenue estimate of $83.64 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX).

Theratechnologies' stock is owned by many different institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (3.32%), Worth Venture Partners LLC (0.81%), Cyndeo Wealth Partners LLC (0.43%), Stifel Financial Corp (0.37%), National Bank of Canada FI (0.28%) and Hamilton Capital LLC (0.18%).

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.